Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tanya Latorre"'
Autor:
Allison C. Rosenthal, Tong Shen, Wei He, Kristy M. Walsh, Heather Walker, Yuqin Song, Mitchell E. Hughes, Han Tun, Laura Leary, Stephen J. Schuster, Emily Leblond, Lijuan Deng, Wei Ding, David L. Porter, Daniel J. Landsburg, Jun Zhu, Sunita D. Nasta, Jakub Svoboda, Kaitlin Kennard, Barry Douglas Anderson, Elizabeth T Chatburn, Scott F. Huntington, Ellen Napier, Anthony R. Mato, Tanya Latorre, Danielle M. Brander, Colleen Dorsey, Victoria Addis, Kylie Boyhen, Jennifer Gill
Publikováno v:
Blood. 132:5384-5384
Background: Synthetic lethality (SL) is characterized by the chemical inhibition of multiple aberrant genes to differentially kill malignant cells. We investigated small-molecule combinations for SL through in vitro and in vivo screening and optimiza
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9dfd82ae3a867b13e74ff9958b254a9b
https://doi.org/10.1182/blood-2018-99-112944
https://doi.org/10.1182/blood-2018-99-112944
Autor:
Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Danielle Land, Kristy M. Walsh, Colleen Timlin, Daniel J. Rubin, Saar Gill, Anthony R. Mato, Donald E. Tsai, Jessica K. Altman, Brenda K. Shelly, Alicia McLeish, Kyle W. Robinson, Donna Capozzi, Mitchell E. Hughes, Tanya Latorre, Allison Rago, Jennifer Gill, Daniel J. Landsburg, James N. Gerson
Publikováno v:
Blood. 132:1706-1706
Introduction: Venetoclax (VEN) is a highly effective agent for chronic lymphocytic leukemia (CLL) that targets BCL-2. Thus, it has been hypothesized to have efficacy in NHL and tested in phase-1/2 studies (Gerecitano JF, Blood 2015; de Vos S, Blood 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6418f6280a9cc3285ef6c87e2722782d
https://doi.org/10.1182/blood-2018-99-111194
https://doi.org/10.1182/blood-2018-99-111194
Autor:
Colleen Timlin, Kaitlin Kennard, Mitchell E. Hughes, William Surkis, Sunita D. Nasta, Jakub Svoboda, Colleen Dorsey, Elizabeth T Chatburn, Anthony R. Mato, Krista Isaac, Molly Fanning, Daniel J. Landsburg, Stephen J. Schuster, Catherine Daniel, Jennifer Gill, Tanya Latorre
Publikováno v:
Journal of Clinical Oncology. 35:e19043-e19043
e19043 Background: Ibrutinib (IBR), a BTK inhibitor, is FDA approved for CLL, Waldenstrom macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma. Despite limited data, IBR is being utilized as a therapy for patients (pts) with relapsed/re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4dd3b96eaedcda070903dbc16b21b0b
https://doi.org/10.1200/jco.2017.35.15_suppl.e19043
https://doi.org/10.1200/jco.2017.35.15_suppl.e19043
Autor:
Tanya Latorre, Danielle M. Brander, David L. Porter, Stephen J. Schuster, Ellen Napier, Daniel J. Landsburg, Anthony R. Mato, Victoria Addis, Sunita D. Nasta, Jakub Svoboda, Wei He, Jennifer Gill, Barry Douglas Anderson, Elizabeth T Chatburn, Kaitlin Kennard
Publikováno v:
Journal of Clinical Oncology. 35:TPS7570-TPS7570
TPS7570 Background: Synthetic lethality (SL) relies on the chemical inhibition of two aberrant genes to selectively kill malignant cells. SL is now a clinical reality in an era of multiple targeted agents and advanced genetic testing. We investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e97b03397bfd2979b32289eea2621e31
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7570
https://doi.org/10.1200/jco.2017.35.15_suppl.tps7570